

Cai Yuan

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/536927/cai-yuan-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|-------------------|-------------------------|----------------|-----------------|
| 54 papers | 990 citations | 17 h-index | 30 g-index |
| 62 ext. papers | 1,201 ext. citations | 6.2 avg, IF | 4.06 L-index |

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 54 | A Clot-Homing Near-Infrared Probe for In Vivo Imaging of Murine Thromboembolic Models.. <i>Advanced Healthcare Materials</i> , 2022 , e2102213 | 10.1 | 0 |
| 53 | A versatile insertion point on albumin to accommodate peptides and maintain their activities.. <i>International Journal of Biological Macromolecules</i> , 2022 , 205, 49-49 | 7.9 | 0 |
| 52 | Crystal structure and cellular functions of uPAR dimer.. <i>Nature Communications</i> , 2022 , 13, 1665 | 17.4 | 2 |
| 51 | Vascular thiol isomerases: Structures, regulatory mechanisms, and inhibitor development. <i>Drug Discovery Today</i> , 2021 , 27, 626-626 | 8.8 | 1 |
| 50 | Development of inhibitors for uPAR: blocking the interaction of uPAR with its partners. <i>Drug Discovery Today</i> , 2021 , 26, 1076-1085 | 8.8 | 12 |
| 49 | A supramolecular nanocarrier for efficient cancer imaging and therapy by targeting at matriptase. <i>Journal of Controlled Release</i> , 2021 , 334, 153-163 | 11.7 | 1 |
| 48 | Development of a Potent Antimicrobial Peptide With Photodynamic Activity. <i>Frontiers in Microbiology</i> , 2021 , 12, 624465 | 5.7 | 1 |
| 47 | Serum Levels of Soluble Platelet Endothelial Cell Adhesion Molecule 1 in COVID-19 Patients Are Associated With Disease Severity. <i>Journal of Infectious Diseases</i> , 2021 , 223, 178-179 | 7 | 13 |
| 46 | A general strategy to inhibit serine protease by targeting its autolysis loop. <i>FASEB Journal</i> , 2021 , 35, e21259 | 0.9 | 6 |
| 45 | Potent inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 by photosensitizers compounds. <i>Dyes and Pigments</i> , 2021 , 194, 109570 | 4.6 | 2 |
| 44 | Inhibition of the Citrus Canker Pathogen Using a Photosensitizer Assisted by Sunlight Irradiation. <i>Frontiers in Microbiology</i> , 2020 , 11, 571691 | 5.7 | 4 |
| 43 | Crystal Structures of Human C4.4A Reveal the Unique Association of Ly6/uPAR/Eheurotoxin Domain. <i>International Journal of Biological Sciences</i> , 2020 , 16, 981-993 | 11.2 | 3 |
| 42 | Plasma levels of the active form of suPAR are associated with COVID-19 severity. <i>Critical Care</i> , 2020 , 24, 704 | 10.8 | 8 |
| 41 | Enhanced Antitumor Efficacy and Imaging Application of Photosensitizer-Formulated Paclitaxel. <i>ACS Applied Materials & Interfaces</i> , 2020 , 12, 4221-4230 | 9.5 | 6 |
| 40 | Improved therapeutic efficacy of quercetin-loaded polymeric nanoparticles on triple-negative breast cancer by inhibiting uPA.. <i>RSC Advances</i> , 2020 , 10, 34517-34526 | 3.7 | 5 |
| 39 | Specifically targeting cancer proliferation and metastasis processes: the development of matriptase inhibitors. <i>Cancer and Metastasis Reviews</i> , 2019 , 38, 507-524 | 9.6 | 11 |
| 38 | A novel ELISA for the detection of active form of plasminogen activator inhibitor-1 based on a highly specific trapping agent. <i>Analytica Chimica Acta</i> , 2019 , 1053, 98-104 | 6.6 | 6 |

| | | | |
|----|---|-------|----|
| 37 | Crystal structure of the unoccupied murine urokinase-type plasminogen activator receptor (uPAR) reveals a tightly packed DII-DIII unit. <i>FEBS Letters</i> , 2019 , 593, 1236-1247 | 3.8 | 4 |
| 36 | Structural determination of group A Streptococcal surface dehydrogenase and characterization of its interaction with urokinase-type plasminogen activator receptor. <i>Biochemical and Biophysical Research Communications</i> , 2019 , 510, 539-544 | 3.4 | |
| 35 | Nanoparticle Binding to Urokinase Receptor on Cancer Cell Surface Triggers Nanoparticle Disintegration and Cargo Release. <i>Theranostics</i> , 2019 , 9, 884-899 | 12.1 | 17 |
| 34 | Solution Structure of SpoIVB Reveals Mechanism of PDZ Domain-Regulated Protease Activity. <i>Frontiers in Microbiology</i> , 2019 , 10, 1232 | 5.7 | 2 |
| 33 | Structural basis of sequence-specific Holliday junction cleavage by MOC1. <i>Nature Chemical Biology</i> , 2019 , 15, 1241-1248 | 11.7 | 10 |
| 32 | tPA Point Mutation at Autolysis Loop Enhances Resistance to PAI-1 Inhibition and Catalytic Activity. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 77-86 | 7 | 2 |
| 31 | A novel purification procedure for recombinant human serum albumin expressed in <i>Pichia pastoris</i> . <i>Protein Expression and Purification</i> , 2018 , 149, 37-42 | 2 | 8 |
| 30 | Dissociation of zinc phthalocyanine aggregation on bacterial surface is key for photodynamic antimicrobial effect. <i>Journal of Porphyrins and Phthalocyanines</i> , 2018 , 22, 925-934 | 1.8 | 17 |
| 29 | Molecular basis of rutin inhibition of protein disulfide isomerase (PDI) by combined and experimental methods.. <i>RSC Advances</i> , 2018 , 8, 18480-18491 | 3.7 | 6 |
| 28 | Halogen bonding for the design of inhibitors by targeting the S1 pocket of serine proteases.. <i>RSC Advances</i> , 2018 , 8, 28189-28197 | 3.7 | 7 |
| 27 | A structural mechanism of flavonoids in inhibiting serine proteases. <i>Food and Function</i> , 2017 , 8, 2437-2443 | 4.3 | 27 |
| 26 | The crystal structure of a multidomain protease inhibitor (HAI-1) reveals the mechanism of its auto-inhibition. <i>Journal of Biological Chemistry</i> , 2017 , 292, 8412-8423 | 5.4 | 7 |
| 25 | Recombinant hepatocyte growth factor activator inhibitor 1: expression in <i>Drosophila</i> S2 cells, purification and crystallization. <i>Acta Crystallographica Section F, Structural Biology Communications</i> , 2017 , 73, 45-50 | 1.1 | 1 |
| 24 | Expression and crystallographic studies of the D1D2 domains of C4.4A, a homologous protein to the urokinase receptor. <i>Acta Crystallographica Section F, Structural Biology Communications</i> , 2017 , 73, 486-490 | 1.1 | 1 |
| 23 | A long-acting PAI-1 inhibitor reduces thrombus formation. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1338-1347 | 13.47 | 20 |
| 22 | Be Active or Not: the Relative Contribution of Active and Passive Tumor Targeting of Nanomaterials. <i>Nanotheranostics</i> , 2017 , 1, 346-357 | 5.6 | 56 |
| 21 | Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor. <i>Angewandte Chemie</i> , 2016 , 128, 3706-3710 | 3.6 | 15 |
| 20 | Dimer conformation of soluble PECAM-1, an endothelial marker. <i>International Journal of Biochemistry and Cell Biology</i> , 2016 , 77, 102-108 | 5.6 | 8 |

| | | | |
|----|---|------|----|
| 19 | Structural basis of specific inhibition of tissue-type plasminogen activator by plasminogen activators inhibitor-1. <i>Data in Brief</i> , 2016 , 6, 550-5 | 1.2 | 2 |
| 18 | Re-engineering the Immune Response to Metastatic Cancer: Antibody-Recruiting Small Molecules Targeting the Urokinase Receptor. <i>Angewandte Chemie - International Edition</i> , 2016 , 55, 3642-6 | 16.4 | 43 |
| 17 | An ELISA method detecting the active form of suPAR. <i>Talanta</i> , 2016 , 160, 205-210 | 6.2 | 6 |
| 16 | Crystal structures of the ligand-binding region of uPARAP: effect of calcium ion binding. <i>Biochemical Journal</i> , 2016 , 473, 2359-68 | 3.8 | 10 |
| 15 | A specific plasminogen activator inhibitor-1 antagonist derived from inactivated urokinase. <i>Journal of Cellular and Molecular Medicine</i> , 2016 , 20, 1851-60 | 5.6 | 20 |
| 14 | Stabilizing a flexible interdomain hinge region harboring the SMB binding site drives uPAR into its closed conformation. <i>Journal of Molecular Biology</i> , 2015 , 427, 1389-1403 | 6.5 | 22 |
| 13 | Quercetin-3-rutinoside Inhibits Protein Disulfide Isomerase by Binding to Its b α W Domain. <i>Journal of Biological Chemistry</i> , 2015 , 290, 23543-52 | 5.4 | 57 |
| 12 | Crystal Structure of the Michaelis Complex between Tissue-type Plasminogen Activator and Plasminogen Activators Inhibitor-1. <i>Journal of Biological Chemistry</i> , 2015 , 290, 25795-804 | 5.4 | 28 |
| 11 | Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography. <i>Data in Brief</i> , 2015 , 5, 107-13 | 1.2 | 9 |
| 10 | A drug carrier targeting murine uPAR for photodynamic therapy and tumor imaging. <i>Acta Biomaterialia</i> , 2015 , 23, 116-126 | 10.8 | 12 |
| 9 | Expression and crystallographic studies of the ligand-binding region of the human endocytic collagen receptor uPARAP. <i>Acta Crystallographica Section F, Structural Biology Communications</i> , 2015 , 71, 1442-7 | 1.1 | 2 |
| 8 | A novel tumor targeting drug carrier for optical imaging and therapy. <i>Theranostics</i> , 2014 , 4, 642-59 | 12.1 | 54 |
| 7 | Rezymogenation of active urokinase induced by an inhibitory antibody. <i>Biochemical Journal</i> , 2013 , 449, 161-6 | 3.8 | 20 |
| 6 | Crystal structures of matriptase in complex with its inhibitor hepatocyte growth factor activator inhibitor-1. <i>Journal of Biological Chemistry</i> , 2013 , 288, 11155-64 | 5.4 | 28 |
| 5 | Crystal structure of the urokinase receptor in a ligand-free form. <i>Journal of Molecular Biology</i> , 2012 , 416, 629-41 | 6.5 | 41 |
| 4 | Structure of catalytic domain of Matriptase in complex with Sunflower trypsin inhibitor-1. <i>BMC Structural Biology</i> , 2011 , 11, 30 | 2.7 | 44 |
| 3 | Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1. <i>Journal of Structural Biology</i> , 2007 , 160, 1-10 | 3.4 | 45 |
| 2 | Protein expression and preliminary crystallographic analysis of amino-terminal fragment of urokinase-type plasminogen activator. <i>Protein Expression and Purification</i> , 2006 , 49, 71-7 | 2 | 11 |

- 1 Structure of human urokinase plasminogen activator in complex with its receptor. *Science*, **2006**, 311, 656-9 333 242